Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Energy to Drive Translocation01:37

Energy to Drive Translocation

2.7K
Mitochondrial protein import is powered by two distinct energy sources: ATP hydrolysis and electrochemical potential across the inner membrane. Newly synthesized precursors are bound by cytosolic chaperones of the Hsp70 family, which guide them to the import receptors on the mitochondrial surface. Utilizing the energy of ATP hydrolysis, Hsp70 chaperones transfer these precursors to the TOM receptors on the mitochondrial outer membrane.
Generally, polypeptides are unfolded by two distinct...
2.7K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.4K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.4K
Drive-Reduction Theory: Push Theory of Motivation01:27

Drive-Reduction Theory: Push Theory of Motivation

1.2K
Clark Hull's drive-reduction theory, introduced in the 1940s and 1950s and often termed the "push theory" of motivation, provides a framework for understanding how biological and learned drives influence behavior. Hull suggested that motivation originates from the need to alleviate physiological tension caused by unmet biological necessities. The theory proposes that when a basic need, such as hunger or sleep, goes unfulfilled, it creates an internal imbalance. This imbalance, or...
1.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.0K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

854
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
854
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

974
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
974

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Movement Disorder Spectrum of ATP1A3-Related Disorders: Cross-Sectional Analysis and Video Archive of 88 Patients.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Convergence Deficits in Myoclonus-Dystonia Point to Cerebellar Impairment.

Movement disorders clinical practice·2026
Same author

How many do we miss? - Evaluation of age at onset and family history as selection criteria for genetic testing in Parkinson's disease.

medRxiv : the preprint server for health sciences·2026
Same author

Association of alcohol responsiveness and non-motor symptoms in isolated adult-onset dystonia.

Journal of neurology·2025
Same author

X-Linked Dystonia-Parkinsonism in a Manifesting Female: First Case Report of Deep Brain Stimulation.

Movement disorders clinical practice·2025
Same author

How to communicate and what to disclose to participants in a recall-by-genotype research approach: a multistep empirical study.

Journal of community genetics·2024

Related Experiment Video

Updated: Jan 26, 2026

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research
07:15

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research

Published on: December 18, 2020

4.9K

Will genotype drive treatment options?

Norbert Brüggemann1,2, Christine Klein1

  • 1Institute of Neurogenetics, University of Lübeck, Lübeck, Germany.

Movement Disorders : Official Journal of the Movement Disorder Society
|April 11, 2019
PubMed
Summary
This summary is machine-generated.

Genetic testing is crucial for diagnosing hereditary movement disorders, guiding treatment, and developing targeted therapies. However, challenges remain in interpreting results and creating effective gene-specific treatments.

Keywords:
genetic testinggenotypegenotype-treatment relationshiphereditary movement disorderstreatment

More Related Videos

Driving Under the Influence: How Music Listening Affects Driving Behaviors
07:25

Driving Under the Influence: How Music Listening Affects Driving Behaviors

Published on: March 27, 2019

13.0K
Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

2.5K

Related Experiment Videos

Last Updated: Jan 26, 2026

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research
07:15

Tactile Vibrating Toolkit and Driving Simulation Platform for Driving-Related Research

Published on: December 18, 2020

4.9K
Driving Under the Influence: How Music Listening Affects Driving Behaviors
07:25

Driving Under the Influence: How Music Listening Affects Driving Behaviors

Published on: March 27, 2019

13.0K
Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
04:11

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease

Published on: April 28, 2023

2.5K

Area of Science:

  • Genetics and Neurology
  • Movement Disorders
  • Personalized Medicine

Background:

  • Individual genetic variations significantly influence movement disorder presentation and treatment response.
  • Advances in genetic discovery and testing identify more patients with hereditary movement disorders.
  • Genetic diagnosis impacts patient counseling and therapeutic strategies.

Purpose of the Study:

  • To highlight the importance of genetic diagnosis in movement disorders.
  • To discuss the potential for gene-targeted therapies.
  • To identify current challenges in genetic testing and treatment development.

Main Methods:

  • Review of current literature on genetic testing in movement disorders.
  • Analysis of the impact of genetic diagnosis on clinical practice.
  • Discussion of emerging gene-targeted treatment strategies and clinical trial design.

Main Results:

  • Genetic diagnosis is increasingly identifying specific hereditary movement disorders.
  • Gene-targeted therapies show promise but are not yet widely available.
  • Inconclusive genetic test results and lack of specific treatments remain significant hurdles.

Conclusions:

  • Establishing a genetic diagnosis is vital for personalized patient care and treatment decisions in movement disorders.
  • While gene-targeted therapies are emerging, significant challenges persist in their development and implementation.
  • Further research is needed to overcome limitations in genetic testing interpretation and to advance causal treatment options for hereditary movement disorders.